Catalyst Wire Dossier Catalyst Wire Dossier

Three-Antigen Leishmania Polyprotein Vaccine with MPL-SE

· Access to Advanced Health Institute (AAHI)
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Three-Antigen Leishmania Polyprotein Vaccine with MPL-SE, covering 2015-04-03 to 2015-04-03. Get the full timeline:

Most recent: Clinical Trial Update: Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in India [Phase 1]

See pricing